Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.52 |
| ▸ | DRD1 | P21728 | 6/20 | 0.52 |
| ▸ | DRD5 | P21918 | 6/20 | 0.52 |
| ▸ | DRD3 | P35462 | 6/20 | 0.52 |
| ▸ | DRD4 | P21917 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30534778 | 1.00 | DRD2 (0.52) | DRD2DRD1DRD5DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL29836377 | 0.98 | KCNH2 (0.53) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL31432671 | 0.95 | DRD2 (0.51) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL10371800 | 0.89 | DRD2 (0.55) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL578280 | 0.86 | KDM4E (0.44) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL30563599 | 0.86 | KDM4E (0.44) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL22681950 | 0.82 | KCNH2 (0.47) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL22681979 | 0.82 | KCNH2 (0.44) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL14857587 | 0.82 | CTNNB1 (0.50) | KCNH2CTNNB1WNT3A | |
| N-Benzylmethylamine SCHEMBL9464717 | 0.82 | KCNH2 (0.47) | DRD2DRD1DRD5DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981260-B1 | NOVEL ANALOGUES OF EPICATECHIN AND RELATED POLYPHENOLS | SPHAERA PHARMA PRIVATE LTD (IN) | 2021-01-13 | — | — | EP | disclosed |
| US-9561272-B2 | Compositions and methods for modulating immune responses | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-02-07 | — | — | US | disclosed |
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-08-06 | — | — | US | disclosed |
| US-20150202285-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-07-23 | — | — | US | disclosed |
| US-9017697-B2 | Compositions and methods for modulating immune responses | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-04-28 | — | — | US | disclosed |
| US-20100151000-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES | THE UNIVERSITY OF QUEENSLAND (AU) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | HLA-DRB1, CD74, CHI3L1 | DRD2 4788/4885DRD1 4859/4885DRD5 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.